Cryoport's First Positive EBITDA Cuts Both Ways: Is This a Turn or a CGT Recovery Trade?

Why the quarter matters

Cryoport's second quarter improved the narrative, but it did not settle it. The key question is whether the company has started to build a repeatable operating model or whether investors are still riding a cell and gene therapy recovery story that could cool quickly.

The main checkpoints are straightforward. 8% year-over-year revenue growth to $49.0 million is a meaningful improvement over contraction, and about $400,000 in positive adjusted EBITDA from continuing operations shows that profitability is no longer purely theoretical. Management also reaffirming its full-year revenue outlook of $192 million to $196 million, which suggests it is not asking investors to assume an easier base case. The next report needs to show whether this quarter was the start of a trend rather than a one-quarter inflection.

The bullish case is real: growth held up, guidance was maintained, and management has argued that more operating leverage should follow as network utilization rises. The cautious case is also reasonable: about $400,000 of positive adjusted EBITDA is only modestly positive, leaving room for reversion if demand softens or execution slips.

Why the revenue mix matters

What changed this quarter is not just the move toward positive EBITDA, but also the mix of revenue supporting it. Life Sciences Services revenue increased 15%, while BioStorage/BioServices revenue grew 25%. That mix matters because services tend to be more repeatable than basic transport, and they can leverage the network more effectively as volume rises.

What the mix shift tells investors

This is the mechanism bulls want to see. More services exposure, combined with broader commercial and late-stage trial activity, can support customer stickiness and better margin conversion over time. Cryoport said it was Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of June 30, 2026. Later-stage and commercial work is usually more mission-critical, which can make a logistics provider harder to replace.

The commercial side is already moving in a healthier direction. Total revenue from the support of commercial CGT grew 9% year-over-year to $9.4 million, and The Life Science Services portion of our revenue from supporting commercial CGT grew 26% year-over-year as the number of patients treated in the community setting and on an outpatient basis continued to ramp. That is not proof of a durable moat by itself, but it does suggest the business is becoming less dependent on pure trial-cycle momentum.

The durability test is still open

The cautious case is simpler: demand can still move quarter to quarter. Trial activity can end, slow, or shift for funding, regulatory, or operational reasons, and that risk has not disappeared.

For now, the evidence points two ways at once. The quarter showed better growth, a more favorable mix, and a first real step toward sustainable profitability. But the EBITDA result is still small enough that investors need more evidence before calling this a fully durable turnaround. The next few quarters need to show that the mix shift is sticking and that margin conversion can repeat.